Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

By Louise Sommerfeld On Oct 20, 2021

Small Pharma Inc. (CVE: DMT)(OTCMKTS: DMTTF), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its successful upgrade from the OTC Pink to the OTCQB^® Venture Market (the “OTCQB”), a United States trading platform that is operated by the OTC Markets Group Inc. in New York. The common shares of the Company will continue to trade on the TSX Venture Exchange (the “TSXV”) under the symbol “DMT”. The Company has also received Depository Trust Company (“DTC”) eligibility to support trading on the OTCQB. Small Pharma will commence trading on the OTCQB as of market open on Wednesday October 20, 2021, under the symbol “DMTTF”.

Trading on the OTCQB furthers our strategy to broaden access for investors to support Small Pharma and our vision of helping millions of patients suffering from mental health conditions with our DMT-assisted psychedelic therapies. With this enhanced access to the significant U.S. market, our recent successful $58 million financing and subsequent listing on the TSXV, we are well-placed to advance our portfolio, including completing the Phase I/IIa clinical trial for our lead product, SPL026, for the treatment of major depression. We look forward to trading on the OTCQB and providing updates as we advance our clinical objectives.
Peter Rands, Chief Executive Officer of Small Pharma

The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. As a verified market with efficient access for U.S. investors, OTCQB helps companies to potentially build their visibility, expand their liquidity, and diversify their shareholder base on an established U.S. public market. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process.

To view the original press release in its entirety click here